The First Case of HER2+ Invasive Ductal Carcinoma Arising From a Breast Hamartoma and Literature Review

التفاصيل البيبلوغرافية
العنوان: The First Case of HER2+ Invasive Ductal Carcinoma Arising From a Breast Hamartoma and Literature Review
المؤلفون: Sherise Chantell Rogers, Carmen Tornos, Lea Baer, Patricia Farrelly, Keith Sweeney
المصدر: Journal of the National Medical Association. 109(1)
سنة النشر: 2016
مصطلحات موضوعية: congenital, hereditary, and neonatal diseases and abnormalities, Pathology, medicine.medical_specialty, Receptor, ErbB-2, medicine.medical_treatment, Hamartoma, Breast Neoplasms, Malignancy, 030218 nuclear medicine & medical imaging, 03 medical and health sciences, Breast Diseases, 0302 clinical medicine, Breast cancer, Biopsy, medicine, Humans, Neoplasm Invasiveness, Breast, Molecular Targeted Therapy, Precision Medicine, skin and connective tissue diseases, neoplasms, Neoplasm Staging, medicine.diagnostic_test, business.industry, Lumpectomy, Carcinoma, Ductal, Breast, General Medicine, Middle Aged, medicine.disease, Prognosis, 030220 oncology & carcinogenesis, Invasive lobular carcinoma, Female, Hormone therapy, business, Calcification, Mammography
الوصف: Carcinomas arising from breast hamartomas are exceedingly rare. We present the first reported case of an African-American female presenting with a right breast lump and a subsequent mammogram suggestive of a hamartoma. She later underwent lumpectomy and was found to have HER2+ invasive ductal carcinoma (IDC) arising from a hamartoma. She was amenable to HER2-targeted trastuzumab, hormone therapy and adjuvant radiation but declined chemotherapy. In a review of the literature, IDC is the predominant neoplastic type found in hamartomas. The average hamartoma size at time of neoplasm diagnosis is 6.0 cm. Patients with hamartomas greater than 6.0 cm, with changes in calcification pattern; new nodules or asymmetry should be considered for additional evaluation with ultrasound, MRI and/or biopsy. HER2 status is under-reported among cases and should be evaluated in any malignancy found within hamartomas as HER-2 therapy has improved overall survival and recurrence free survival in HER2+breast cancer patients.
تدمد: 0027-9684
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74fd4e55d66b47d6c161f6d742f0e4ba
https://pubmed.ncbi.nlm.nih.gov/28259217
حقوق: CLOSED
رقم الأكسشن: edsair.doi.dedup.....74fd4e55d66b47d6c161f6d742f0e4ba
قاعدة البيانات: OpenAIRE